Moleculin Biotech (NASDAQ:MBRX) Releases Quarterly Earnings Results, Misses Estimates By $1.85 EPS

Moleculin Biotech (NASDAQ:MBRX) issued its earnings results on Thursday. The company reported ($3.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($1.85), FiscalAI reports.

Moleculin Biotech Stock Down 4.1%

NASDAQ MBRX opened at $2.11 on Friday. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $25.00. The company has a market capitalization of $11.27 million, a PE ratio of -0.06 and a beta of 1.74. The firm’s 50 day moving average is $2.33 and its 200-day moving average is $4.72.

Analyst Upgrades and Downgrades

MBRX has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $22.00.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.